Case Report

Mepolizumab and Eosinophilic Pleural Effusion in Patient With Eosinophilic Granulomatosis With Polyangiitis

María del Carmen Lorenzo Martínez a,*, Oscar Clavería García a, María Dolores Herrero Mendoza b, José Javier Jareño Esteban a

a Pneumology Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain
b Internal Medicine Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain

We present a 71-year-old woman with a long-standing history of severe eosinophilic asthma (controlled with ACT scale of 15) and nasal polyposis, with suspected poor adherence to treatment at follow-up.

The patient was admitted to our hospital with clinical manifestations of cough and whitish expectoration. During physical examination, partial respiratory failure and semiology of asthmatic exacerbation with hypophonesis in lower pulmonary lobes were found. X-ray, and then chest CT, were requested showing consolidation in the upper lobes and bilateral pleural effusion (Fig. 1). Laboratory data showed no biochemistry alterations, NT-proBNP 262 pg/ml, CRP 2.62 mg/dl and leukocytosis 15,180/mcL (eosinophils 3,990/mcL, 27%). The ANAs, MPO-ANCA, PR3-ANCA, microbiology and serology were all negative (virus, bacteria and parasites).

In view of patient’s poor respiratory progress, we performed a diagnostic thoracentesis, obtaining a yellowish non-hematic exudate with the following characteristics: pH 7.20, protein 6 g/dl, glucose 214 mg/dl, LDH 203 U/L and leukocytes 6780/mcL (50% eosinophils). Cytology and microbiology were negative. It was decided to carry out a nasal turbinate biopsy, that showed eosinophilic infiltration of the corium. Polyneuropathy was ruled out.

EGPA was diagnosed classifying it as a nonsevere with a “Five Factor Score” (FFS) of zero. Treatment was started with prednisone 50 mg and mepolizumab 100 mg per day, progressively escalating to mepolizumab 300 mg per day. After 6 months of full-dose treatment, the patient presented an excellent clinical and radiological improvement with complete resolution of eosinophilic pleural effusion (EPE).

According to the American College of Rheumatology (1990), more than 4 of the next 6 criteria are necessary for EGPA diagnosis: asthma, peripheral eosinophilia (>10%), neuropathy, sinusitis, extravascular eosinophilia and evanescent pulmonary infiltrates.

Fig. 1. Chest CT. Left image: bilateral pleural effusion predominantly on the left side with secondary passive atelectasis. Right image: bilateral infiltrates.

* Corresponding author.
E-mail address: carmenlorenzomtz@gmail.com
(M.C. Lorenzo Martínez Martínez).

https://doi.org/10.1016/j.arbes.2023.03.014
0300-2896/© 2023 SEPAR. Published by Elsevier España, S.L.U. All rights reserved.
Eosinophilic pleural effusion is a rare complication,\textsuperscript{2} with an incidence of 29% in patients with EGPA. Its characteristics have not been well described, having been defined by more than 10% eosinophil count, low pH and low glucose. Differential diagnoses of EPE include rheumatoid arthritis, bacterial pneumonia, tuberculosis, parasitosis, pharmacological, neoplasms, hematological disorders and, less frequently, certain vasculitis.

There is no standard therapy for the management of EGPA.\textsuperscript{3} Currently, the cornerstone of treatment consist of systemic glucocorticosteroids, with a relapse rate of 35%. In this context, immunosuppressive agents are used for maintaining remission. In spite of that, high dose of glucocorticoids and immunosuppressants may have long-term adverse effects. Recently, clinical benefits of mepolizumab have been demonstrated in patients with EGPA. MIRRA trial\textsuperscript{4} included patients with refractory EGPA treated with prednisone, demonstrating remission in 87% of patients treated with mepolizumab versus 53% in the placebo group. An European Observacional Study compared mepolizumab 300 mg versus 100 mg dose, showing both doses are associated with effective control of systemic EGPA manifestations.\textsuperscript{5}

Therefore, mepolizumab is now a good therapeutic option for EGPA. It should be considered as a steroid-sparing drug used for maintenance of remission and control of non-organ-threatening flares, but not as a treatment for active organ-threatening disease.

**Conflict of interests**

The authors state that they have no conflict of interests.

**References**